Skip to main content
Top
Published in: Vascular Cell 1/2012

Open Access 01-12-2012 | Research

Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1

Authors: Jerzy Krupinski, Manal Abudawood, Sabine Matou-Nasri, Raid Al-Baradie, Eugen Bogdan Petcu, Carlos Justicia, Anna Planas, Donghui Liu, Norma Rovira, Marta Grau-Slevin, Julio Secades, Mark Slevin

Published in: Vascular Cell | Issue 1/2012

Login to get access

Abstract

Background

Citicoline is one of the neuroprotective agents that have been used as a therapy in stroke patients. There is limited published data describing the mechanisms through which it acts.

Methods

We used in vitro angiogenesis assays: migration, proliferation, differentiation into tube-like structures in Matrigel™ and spheroid development assays in human brain microvessel endothelial cells (hCMEC/D3). Western blotting was performed on protein extraction from hCMEC/D3 stimulated with citicoline. An analysis of citicoline signalling pathways was previously studied using a Kinexus phospho-protein screening array. A staurosporin/calcium ionophore-induced apoptosis assay was performed by seeding hCMEC/D3 on to glass coverslips in serum poor medium. In a pilot in vivo study, transient MCAO in rats was carried out with and without citicoline treatment (1000 mg/Kg) applied at the time of occlusion and subsequently every 3 days until euthanasia (21 days). Vascularity of the stroke-affected regions was examined by immunohistochemistry.

Results

Citicoline presented no mitogenic and chemotactic effects on hCMEC/D3; however, it significantly increased wound recovery, the formation of tube-like structures in Matrigel™ and enhanced spheroid development and sprouting. Citicoline induced the expression of phospho-extracellular-signal regulated kinase (ERK)-1/2. Kinexus assays showed an over-expression of insulin receptor substrate-1 (IRS-1). Knock-down of IRS-1 with targeted siRNA in our hCMEC/D3 inhibited the pro-angiogenic effects of citicoline. The percentage of surviving cells was higher in the presence of citicoline. Citicoline treatment significantly increased the numbers of new, active CD105-positive microvessels following MCAO.

Conclusions

The findings demonstrate both a pro-angiogenic and protective effect of citicoline on hCMEC/D3 in vitro and following middle cerebral artery occlusion (MCAO) in vivo.
Appendix
Available only for authorised users
Literature
1.
go back to reference Secades JJ: Probably role of citicoline in stroke rehabilitation: review of the literature. Rev Neurol. 2012, 54 (3): 173-179.PubMed Secades JJ: Probably role of citicoline in stroke rehabilitation: review of the literature. Rev Neurol. 2012, 54 (3): 173-179.PubMed
2.
go back to reference Blount PJ, Nguyen CD, McDeavitt JT: Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002, 17: 314-321. 10.1097/00001199-200208000-00005.CrossRefPubMed Blount PJ, Nguyen CD, McDeavitt JT: Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002, 17: 314-321. 10.1097/00001199-200208000-00005.CrossRefPubMed
3.
go back to reference Hurtado O, Cárdenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, et al: A chronic treatmente with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis. 2007, 26: 105-111. 10.1016/j.nbd.2006.12.005.CrossRefPubMed Hurtado O, Cárdenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, et al: A chronic treatmente with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis. 2007, 26: 105-111. 10.1016/j.nbd.2006.12.005.CrossRefPubMed
4.
go back to reference Davalos A, Secades J: Citicoline preclinical and clinical update 2009–2010. Stroke. 2011, 42: S36-S39. 10.1161/STROKEAHA.110.605568.CrossRefPubMed Davalos A, Secades J: Citicoline preclinical and clinical update 2009–2010. Stroke. 2011, 42: S36-S39. 10.1161/STROKEAHA.110.605568.CrossRefPubMed
5.
go back to reference Lee HJ, Kang JS, Kim YI: Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009, 5: 33-38. 10.3988/jcn.2009.5.1.33.PubMedCentralCrossRefPubMed Lee HJ, Kang JS, Kim YI: Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009, 5: 33-38. 10.3988/jcn.2009.5.1.33.PubMedCentralCrossRefPubMed
6.
go back to reference Giralt D, Garcia-Bonilla L, Campos M, Sosti V, Rosell A, Montaner J: Selecting the optimal dose of citicoline treatment in animal models of focal cerebral ischaemia through a meta-analysis. Cerebrovasc Dis. 2010, 29: 165- Giralt D, Garcia-Bonilla L, Campos M, Sosti V, Rosell A, Montaner J: Selecting the optimal dose of citicoline treatment in animal models of focal cerebral ischaemia through a meta-analysis. Cerebrovasc Dis. 2010, 29: 165-
7.
go back to reference Saver JL: Citicoline: updata on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008, 5: 167-177.PubMed Saver JL: Citicoline: updata on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008, 5: 167-177.PubMed
8.
go back to reference Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R: CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology. 2002, 42: 846-854. 10.1016/S0028-3908(02)00032-1.CrossRefPubMed Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R: CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology. 2002, 42: 846-854. 10.1016/S0028-3908(02)00032-1.CrossRefPubMed
9.
go back to reference Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al: Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005, 19: 1872-1874.PubMed Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al: Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005, 19: 1872-1874.PubMed
10.
go back to reference Slevin M, Matou-Nasri S, Turu M, Luque A, Rovira N, Badimon L, et al: Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol. 2010, 20: 151-165. 10.1111/j.1750-3639.2008.00256.x.CrossRefPubMed Slevin M, Matou-Nasri S, Turu M, Luque A, Rovira N, Badimon L, et al: Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol. 2010, 20: 151-165. 10.1111/j.1750-3639.2008.00256.x.CrossRefPubMed
11.
go back to reference Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989, 20: 84-91. 10.1161/01.STR.20.1.84.CrossRefPubMed Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989, 20: 84-91. 10.1161/01.STR.20.1.84.CrossRefPubMed
12.
go back to reference Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C, Chemtob S: Potent in vivo antiangiogenic effects of GS-101 (5′-TATCCGGAGGGCTCGCCATGCTGCT-3′) an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther. 2009, 329: 496-504. 10.1124/jpet.108.147496.CrossRefPubMed Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C, Chemtob S: Potent in vivo antiangiogenic effects of GS-101 (5′-TATCCGGAGGGCTCGCCATGCTGCT-3′) an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther. 2009, 329: 496-504. 10.1124/jpet.108.147496.CrossRefPubMed
13.
go back to reference Matyja E, Taraszewska A, Naganska E, Grieb P, Rafalowska J: CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. Folia Neuropathol. 2008, 46: 139-148.PubMed Matyja E, Taraszewska A, Naganska E, Grieb P, Rafalowska J: CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. Folia Neuropathol. 2008, 46: 139-148.PubMed
14.
go back to reference Sahin S, Alkran T, Temel SG, Tureyen K, Tolunay S, Korfali E: Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischaemia in rats. J Clin Neurosci. 2010, 17: 227-231. 10.1016/j.jocn.2009.05.016.CrossRefPubMed Sahin S, Alkran T, Temel SG, Tureyen K, Tolunay S, Korfali E: Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischaemia in rats. J Clin Neurosci. 2010, 17: 227-231. 10.1016/j.jocn.2009.05.016.CrossRefPubMed
15.
go back to reference Han YS, Chung IY, Park JM, Yu JM: Neuroprotective effect of citicoline on retinal cell damage induced by kainic acid in rats. Korean J Ophthalmol. 2005, 19: 219-226. 10.3341/kjo.2005.19.3.219.CrossRefPubMed Han YS, Chung IY, Park JM, Yu JM: Neuroprotective effect of citicoline on retinal cell damage induced by kainic acid in rats. Korean J Ophthalmol. 2005, 19: 219-226. 10.3341/kjo.2005.19.3.219.CrossRefPubMed
16.
17.
go back to reference Miquel K, Pradines A, Terce F, Selmi S, Favre G: Competetive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem. 1998, 273: 26179-26186. 10.1074/jbc.273.40.26179.CrossRefPubMed Miquel K, Pradines A, Terce F, Selmi S, Favre G: Competetive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem. 1998, 273: 26179-26186. 10.1074/jbc.273.40.26179.CrossRefPubMed
18.
go back to reference Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al: Apoptotic phosphorylation of histone H2B by mammalian sterile twenty kinase. Cell. 2003, 113: 507-517. 10.1016/S0092-8674(03)00355-6.CrossRefPubMed Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al: Apoptotic phosphorylation of histone H2B by mammalian sterile twenty kinase. Cell. 2003, 113: 507-517. 10.1016/S0092-8674(03)00355-6.CrossRefPubMed
19.
go back to reference Mitsios N, Gaffney J, Kumar P, Krupinski J, Kumar S, Slevin M: Pathophysiology of acute ischaemic stroke: an analysis of common signalling mechanisms and identification of new molecular targets. Pathobiol. 2006, 73: 159-175. 10.1159/000096017.CrossRef Mitsios N, Gaffney J, Kumar P, Krupinski J, Kumar S, Slevin M: Pathophysiology of acute ischaemic stroke: an analysis of common signalling mechanisms and identification of new molecular targets. Pathobiol. 2006, 73: 159-175. 10.1159/000096017.CrossRef
20.
go back to reference Slevin M, Kumar P, Gaffney J, Kumar S, Krupinski J: Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. Clin Sci. 2006, 111: 171-183. 10.1042/CS20060049.CrossRefPubMed Slevin M, Kumar P, Gaffney J, Kumar S, Krupinski J: Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. Clin Sci. 2006, 111: 171-183. 10.1042/CS20060049.CrossRefPubMed
21.
go back to reference Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen E: Down-regulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2005, 46: 4072-4078. 10.1167/iovs.05-0105.CrossRefPubMed Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen E: Down-regulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2005, 46: 4072-4078. 10.1167/iovs.05-0105.CrossRefPubMed
22.
go back to reference Kain H, Goldblum D, Geudelin B, Thorin E, Beglinger C: Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a first in man phase 1 investigation. Br J Clin Pharmacol. 2009, 68: 169-173. 10.1111/j.1365-2125.2009.03450.x.PubMedCentralCrossRefPubMed Kain H, Goldblum D, Geudelin B, Thorin E, Beglinger C: Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a first in man phase 1 investigation. Br J Clin Pharmacol. 2009, 68: 169-173. 10.1111/j.1365-2125.2009.03450.x.PubMedCentralCrossRefPubMed
23.
go back to reference Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT: Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumour and anti-angiogenic responses in vitro and in vivo. J Biol Chem. 2011, 286: 13626-13637. 10.1074/jbc.M110.216820.PubMedCentralCrossRefPubMed Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT: Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumour and anti-angiogenic responses in vitro and in vivo. J Biol Chem. 2011, 286: 13626-13637. 10.1074/jbc.M110.216820.PubMedCentralCrossRefPubMed
24.
go back to reference Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF: HER2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways: implications for HER2 –targeted antibody therapy. Oncogene. 2006, 25: 6986-6996. 10.1038/sj.onc.1209685.CrossRefPubMed Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF: HER2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways: implications for HER2 –targeted antibody therapy. Oncogene. 2006, 25: 6986-6996. 10.1038/sj.onc.1209685.CrossRefPubMed
Metadata
Title
Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1
Authors
Jerzy Krupinski
Manal Abudawood
Sabine Matou-Nasri
Raid Al-Baradie
Eugen Bogdan Petcu
Carlos Justicia
Anna Planas
Donghui Liu
Norma Rovira
Marta Grau-Slevin
Julio Secades
Mark Slevin
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Vascular Cell / Issue 1/2012
Electronic ISSN: 2045-824X
DOI
https://doi.org/10.1186/2045-824X-4-20

Other articles of this Issue 1/2012

Vascular Cell 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.